Forty-nine trials (n=3,566 participants) were included in the meta-analysis. Sample sizes ranged from 11 to 300. The average attrition rate was 7.1% for exercise and 4.4% for control groups.
Exercise versus no-treatment (49 trials): The pooled effect size was -0.48 (95% confidence interval (CI): -0.63 to -0.33), indicating that participants in the exercise group had statistically significant reductions in anxiety when compared to control. The overall weighted gains effect sizes for exercise was -0.43 (95% CI: -0.46 to -0.36) and for control groups was -0.08 (95% CI: -0.13 to -0.04). The authors indicated that there was no significant publication bias. There was significant heterogeneity (p<0.001). Moderator analysis revealed that statistically significant higher effect sizes were reported in participants aged 31 to 45 years, and in those who exercised three to four times per week.
Exercise versus other treatments (27 trials): The pooled effect size was -0.19 (95% CI not reported; p<0.05), indicating that participants in the exercise group had equal or slightly greater reductions in anxiety in all comparison groups, except for pharmacotherapy.
A non-significant trend for the relationship between increased effect size and early rises in exercise dose (but not for higher doses) was noted in the dose-response analysis (12 trials).